SHOCKWAVE MEDICAL INC (SWAV) Stock Fundamental Analysis
USA - NASDAQ:SWAV - US82489T1043 - Common Stock
334.75 USD
-0.08 (-0.02%)
334.8 USD
+0.05 (+0.01%)
Overall SWAV gets a fundamental rating of 6 out of 10. We evaluated SWAV against 189 industry peers in the Health Care Equipment & Supplies industry. SWAV is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. SWAV is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, SWAV could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
SWAV had positive earnings in the past year.
SWAV had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: SWAV reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: SWAV reported negative operating cash flow in multiple years.
1.2 Ratios
SWAV's Return On Assets of 9.95% is amongst the best of the industry. SWAV outperforms 93.23% of its industry peers.
Looking at the Return On Equity, with a value of 21.76%, SWAV belongs to the top of the industry, outperforming 95.31% of the companies in the same industry.
SWAV's Return On Invested Capital of 8.81% is amongst the best of the industry. SWAV outperforms 88.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.95% | ||
| ROE | 21.76% | ||
| ROIC | 8.81% |
ROA(3y)13.4%
ROA(5y)-1.2%
ROE(3y)20.17%
ROE(5y)0.98%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SWAV has a better Profit Margin (20.76%) than 94.79% of its industry peers.
SWAV's Operating Margin of 20.52% is amongst the best of the industry. SWAV outperforms 94.27% of its industry peers.
Looking at the Gross Margin, with a value of 86.99%, SWAV belongs to the top of the industry, outperforming 96.35% of the companies in the same industry.
SWAV's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.52% | ||
| PM (TTM) | 20.76% | ||
| GM | 86.99% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.99%
GM growth 5Y16.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SWAV is destroying value.
SWAV has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SWAV has more shares outstanding
The debt/assets ratio for SWAV is higher compared to a year ago.
2.2 Solvency
SWAV has an Altman-Z score of 10.26. This indicates that SWAV is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 10.26, SWAV belongs to the top of the industry, outperforming 86.98% of the companies in the same industry.
SWAV has a debt to FCF ratio of 4.41. This is a neutral value as SWAV would need 4.41 years to pay back of all of its debts.
SWAV has a Debt to FCF ratio of 4.41. This is amongst the best in the industry. SWAV outperforms 82.81% of its industry peers.
A Debt/Equity ratio of 0.97 indicates that SWAV is somewhat dependend on debt financing.
SWAV's Debt to Equity ratio of 0.97 is on the low side compared to the rest of the industry. SWAV is outperformed by 76.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 10.26 |
ROIC/WACC0.94
WACC9.36%
2.3 Liquidity
A Current Ratio of 13.81 indicates that SWAV has no problem at all paying its short term obligations.
SWAV's Current ratio of 13.81 is amongst the best of the industry. SWAV outperforms 97.92% of its industry peers.
SWAV has a Quick Ratio of 12.61. This indicates that SWAV is financially healthy and has no problem in meeting its short term obligations.
SWAV has a Quick ratio of 12.61. This is amongst the best in the industry. SWAV outperforms 97.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.81 | ||
| Quick Ratio | 12.61 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 12.34% over the past year.
SWAV shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.44%.
The Revenue has been growing by 126.31% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)12.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.81%
Revenue 1Y (TTM)41.44%
Revenue growth 3Y120.84%
Revenue growth 5Y126.31%
Sales Q2Q%35.85%
3.2 Future
SWAV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.56% yearly.
SWAV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.10% yearly.
EPS Next Y36.11%
EPS Next 2Y27.65%
EPS Next 3Y24.15%
EPS Next 5Y17.56%
Revenue Next Year27.69%
Revenue Next 2Y24.82%
Revenue Next 3Y23.61%
Revenue Next 5Y20.1%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
SWAV is valuated quite expensively with a Price/Earnings ratio of 78.21.
Compared to the rest of the industry, the Price/Earnings ratio of SWAV indicates a somewhat cheap valuation: SWAV is cheaper than 67.19% of the companies listed in the same industry.
SWAV's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.11.
SWAV is valuated quite expensively with a Price/Forward Earnings ratio of 53.09.
68.75% of the companies in the same industry are more expensive than SWAV, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.55. SWAV is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.21 | ||
| Fwd PE | 53.09 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SWAV indicates a somewhat cheap valuation: SWAV is cheaper than 67.19% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, SWAV is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 75.65 | ||
| EV/EBITDA | 66.43 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SWAV does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of SWAV may justify a higher PE ratio.
A more expensive valuation may be justified as SWAV's earnings are expected to grow with 24.15% in the coming years.
PEG (NY)2.17
PEG (5Y)N/A
EPS Next 2Y27.65%
EPS Next 3Y24.15%
5. Dividend
5.1 Amount
SWAV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
334.75
-0.08 (-0.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners10.85%
Inst Owner Change0%
Ins Owners5.23%
Ins Owner Change0%
Market Cap12.57B
Revenue(TTM)787.98M
Net Income(TTM)163.55M
Analysts53.75
Price Target330.75 (-1.19%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.32%
Min EPS beat(2)27.98%
Max EPS beat(2)44.66%
EPS beat(4)3
Avg EPS beat(4)18.35%
Min EPS beat(4)-12.88%
Max EPS beat(4)44.66%
EPS beat(8)7
Avg EPS beat(8)24.97%
EPS beat(12)11
Avg EPS beat(12)73.56%
EPS beat(16)13
Avg EPS beat(16)54.46%
Revenue beat(2)1
Avg Revenue beat(2)1.53%
Min Revenue beat(2)-0.23%
Max Revenue beat(2)3.29%
Revenue beat(4)2
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-1.27%
Max Revenue beat(4)3.29%
Revenue beat(8)5
Avg Revenue beat(8)2.94%
Revenue beat(12)9
Avg Revenue beat(12)5.4%
Revenue beat(16)13
Avg Revenue beat(16)8.23%
PT rev (1m)2.57%
PT rev (3m)25.91%
EPS NQ rev (1m)-2.66%
EPS NQ rev (3m)-2.74%
EPS NY rev (1m)6.44%
EPS NY rev (3m)16.18%
Revenue NQ rev (1m)0.35%
Revenue NQ rev (3m)0.36%
Revenue NY rev (1m)0.78%
Revenue NY rev (3m)0.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.21 | ||
| Fwd PE | 53.09 | ||
| P/S | 15.95 | ||
| P/FCF | 75.65 | ||
| P/OCF | 63.5 | ||
| P/B | 16.72 | ||
| P/tB | 20.26 | ||
| EV/EBITDA | 66.43 |
EPS(TTM)4.28
EY1.28%
EPS(NY)6.31
Fwd EY1.88%
FCF(TTM)4.42
FCFY1.32%
OCF(TTM)5.27
OCFY1.57%
SpS20.99
BVpS20.03
TBVpS16.52
PEG (NY)2.17
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.95% | ||
| ROE | 21.76% | ||
| ROCE | 10.42% | ||
| ROIC | 8.81% | ||
| ROICexc | 26.17% | ||
| ROICexgc | 34.98% | ||
| OM | 20.52% | ||
| PM (TTM) | 20.76% | ||
| GM | 86.99% | ||
| FCFM | 21.08% |
ROA(3y)13.4%
ROA(5y)-1.2%
ROE(3y)20.17%
ROE(5y)0.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.99%
GM growth 5Y16.42%
F-Score5
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | 4.41 | ||
| Debt/EBITDA | 4.22 | ||
| Cap/Depr | 270.11% | ||
| Cap/Sales | 4.03% | ||
| Interest Coverage | 30.21 | ||
| Cash Conversion | 114.09% | ||
| Profit Quality | 101.56% | ||
| Current Ratio | 13.81 | ||
| Quick Ratio | 12.61 | ||
| Altman-Z | 10.26 |
F-Score5
WACC9.36%
ROIC/WACC0.94
Cap/Depr(3y)384.02%
Cap/Depr(5y)409.93%
Cap/Sales(3y)4.85%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.81%
EPS Next Y36.11%
EPS Next 2Y27.65%
EPS Next 3Y24.15%
EPS Next 5Y17.56%
Revenue 1Y (TTM)41.44%
Revenue growth 3Y120.84%
Revenue growth 5Y126.31%
Sales Q2Q%35.85%
Revenue Next Year27.69%
Revenue Next 2Y24.82%
Revenue Next 3Y23.61%
Revenue Next 5Y20.1%
EBIT growth 1Y8.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.79%
EBIT Next 3Y41.48%
EBIT Next 5Y38.45%
FCF growth 1Y635%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y478.63%
OCF growth 3YN/A
OCF growth 5YN/A
SHOCKWAVE MEDICAL INC / SWAV FAQ
What is the fundamental rating for SWAV stock?
ChartMill assigns a fundamental rating of 6 / 10 to SWAV.
What is the valuation status of SHOCKWAVE MEDICAL INC (SWAV) stock?
ChartMill assigns a valuation rating of 4 / 10 to SHOCKWAVE MEDICAL INC (SWAV). This can be considered as Fairly Valued.
What is the profitability of SWAV stock?
SHOCKWAVE MEDICAL INC (SWAV) has a profitability rating of 6 / 10.
Can you provide the PE and PB ratios for SWAV stock?
The Price/Earnings (PE) ratio for SHOCKWAVE MEDICAL INC (SWAV) is 78.21 and the Price/Book (PB) ratio is 16.72.
Can you provide the financial health for SWAV stock?
The financial health rating of SHOCKWAVE MEDICAL INC (SWAV) is 7 / 10.